Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company. The company has 6 novel non-opioid products in development to treat pain, with two late-stage products that are phase-3 ready and in phase 2, respectively.

The prevalence of pain in the US reached 178 million adults in 20141 .  Many patients experiencing moderate to severe pain receive prescription opioids, though treatment with opioids comes with inherent risks. Neumentum’s analgesic product candidates have the potential to provide the benefits of safe and effective pain management without the limitations and risks for abuse and misuse, and the side-effects including potential for life-threatening respiratory depression, that come with opioids.

Neumentum is led by a world-class executive team of biotech and pharmaceutical industry leaders who have extensive pain and neurology experience, from drug development through commercialization.


Investor Contact
Patti Bank, Westwicke